Regulators agree to review new gene therapy
EU drug regulators have agreed to review Cerepro, a gene therapy for brain cancer developed by Ark Therapeutics. Ark has presented data that Cerepro can almost double the expected survival times of brain cancer victims.The therapy works by stimulating an enzyme that kills cancer cells.
- read this press release for more information
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
